EMA Authorised: Entyvio (vedolizumab) — Takeda Pharma A/S

View source ↗

Summary

EMA authorises Entyvio (vedolizumab) for use in ulcerative colitis and Crohn's disease with Takeda as MAH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Entyvio (vedolizumab)

Snippet

Status: Authorised. Therapeutic area: Colitis, Ulcerative;Crohn Disease. MAH: Takeda Pharma A/S. Decision date: 15/01/2026